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Abstract
Over a decade of genome-wide association studies (GWAS) have led to the finding of
extreme polygenicity of complex traits. The phenomenon that “all genes affect every com-
plex trait” complicates Mendelian Randomization (MR) studies, where natural genetic
variations are used as instruments to infer the causal effect of heritable risk factors. We
reexamine the assumptions of existing MR methods and show how they need to be clarified
to allow for pervasive horizontal pleiotropy and heterogeneous effect sizes. We propose a
comprehensive framework GRAPPLE to analyze the causal effect of target risk factors with
heterogeneous genetic instruments and identify possible pleiotropic patterns from data.
By using GWAS summary statistics, GRAPPLE can efficiently use both strong and weak
genetic instruments, detect the existence of multiple pleiotropic pathways, determine the
causal direction and perform multivariable MR to adjust for confounding risk factors. With
GRAPPLE, we analyze the effect of blood lipids, body mass index, and systolic blood pres-
sure on 25 disease outcomes, gaining new information on their causal relationships and
potential pleiotropic pathways involved.
Author summary
Mendelian randomization uses genetic variants related to a modifiable risk factor to
obtain evidence regarding its causal influence on disease from observational studies. How-
ever, the highly polygenic nature of complex traits where almost all genes contribute to
every complex trait challenges the reliability of the causal inference from these genetic var-
iants. In this paper, we give a thorough reexamination of the assumptions that can be rea-
sonably made for Mendelian randomization and propose a framework, GRAPPLE, to
gain power by using both strongly and weakly associated SNPs and to identify confound-
ing pleiotropic pathways from hidden risk factors. With GRAPPLE, we analyze the effect
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of blood lipids, body mass index, and systolic blood pressure on 25 diseases, gaining an
improved understanding of these risk factors.
Introduction
Understanding the pathogenic mechanism of common diseases is a fundamental goal in clini-
cal research. As randomized controlled experiments are not always feasible, researchers are
looking towards Mendelian Randomization (MR) as an alternative method for probing the
causal mechanisms of common diseases [1]. MR uses inherited genetic variations as instru-
mental variables (IV) to interrogate the causal effect of heritable risk factor(s) on the disease of
interest. The basic idea is that at these variant loci, the inherited alleles are randomly transmit-
ted from the parents to their offsprings according to Mendel’s laws. Thus, the genotypes are
independent from non-heritable confounding variables which may obfuscate causal estima-
tion in parent-offspring studies. More generally, such independence also approximately holds
for population data such as those collected in genome-wide association studies (GWAS) when
individuals share the same ancestry [2]. With the accumulation of data from GWAS, there is
increasing interest in MR approaches, especially in approaches that only rely on GWAS sum-
mary statistics that are publicly available [2, 3].
How well Mendelian Randomization works depends on how well the genetic variant loci
used as instruments abide by the rules of IV. These rules dictate that, if the genetic locus has an
effect on the disease outcome, it should be only through pathways mediated by the risk factor
(s) of interest. This rule, termed exclusion restriction, is violated when there is horizontal plei-
otropy, defined as the case where the genetic variant can influence the disease through path-
ways other than the given risk factor(s) [4]. There has been much recent attention on this issue
[5–16] in MR, yet our understanding is far from complete. Current methods rely on different
assumptions on the pattern of horizontal pleiotropy, often driven by statistical convenience
rather than what geneticists have learned from real data. What assumptions on pleiotropy and
genetic effects would be suitable? Would it be possible to learn the degree of pleiotropy from
the data? Could we perform model diagnosis utilizing only GWAS summary statistics?
The pleiotropy issue that muddles Mendelian Randomization studies is, in a large part, due
to the fact that complex traits are extremely polygenic [15, 17–24]. Accumulating evidence
from GWAS studies indicates that many complex diseases may have an omnigenic architec-
ture where all genes affect every complex trait [25]. While a few genes might be “core” genes, a
large proportion of genes may have non-zero effects on diseases and their risk factors. Thus, in
an MR study, many genetic instruments, if not all, may affect the disease through their effects
on other unmeasured risk factors. In other words, in an MR analysis, not only would we expect
horizontal pleiotropy to be a pervasive issue across all genetic variants, any disease or complex
risk factor would also be associated with a large number of SNPs across the whole genome.
Many existing MR methods rely on the assumption that pleiotropic effects sparsely involve
only a few SNPs, which directly counters these recent insights. Methods that don’t assume
sparsity often require the instrument strength independent of direct effect (InSIDE) assump-
tion [6], which can be rather optimistic. Recently, a few new methods relaxed the InSIDE
assumption to consider “correlated pleiotropy” through one pleiotropic pathway [11, 12, 15,
26]. However, when pleiotropic pathways exist, there would often be an issue in identifying
the true causal effect of the risk factor, and most methods are restricted to allow for only one
pleiotropy pathway. Armed with these assumptions, most existing methods also utilize only
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the few SNPs that have the strongest association with the risk factor as instruments, ignoring
the SNPs that are weakly associated. In this work, we will show that weakly associated SNPs
are also informative, and that a model combining weak and strong SNPs can increase the accu-
racy and stability of our estimations in some scenarios.
We propose a comprehensive statistical framework for causal effect estimation under the
realistic assumption that pleiotropy may be pervasive across the genome. The framework,
called GRAPPLE (Genome-wide mR Analysis under Pervasive PLEiotropy), facilitates interac-
tive identification of multiple pleiotropic pathways and incorporates all SNPs associated with
the risk factor at varying p-value thresholds into the analysis. GRAPPLE builds upon a previ-
ous statistical framework we developed called MR-RAPS [10] under the InSIDE assumption,
but is much more comprehensive and flexible. GRAPPLE emphasizes the detection of multiple
pleiotropic pathways when the InSIDE assumption is violated as well as the determination of
the causal direction. GRAPPLE further addresses two common challenges: how to jointly esti-
mate the effects with multiple risk factors to reduce correlated pleiotropy, and how to integrate
cohorts with overlapping samples. The estimation accuracy of GRAPPLE is examined through
validations involving both real studies and simulations.
We apply GRAPPLE to investigate the causal effects of 5 risk factors (three plasma lipid
traits, body mass index, and systolic blood pressure) on 25 common diseases. Although there
have been several causal effect screening studies [9, 15, 26] for these risk factors and diseases,
the multi-modality analysis enabled by GRAPPLE brings forth new insights on the pleiotropic
landscape of these diseases and, thus, an improved understanding of the causal risk factors.
Specifically, we will reexamine the role of lipid traits on coronary artery disease and type-II
diabetes, where the results from MR studies have been under heated debate [2, 27, 28]. The




From the causal model to GWAS summary statistics. Our framework starts with a set of
structural equations that jointly specify the generative model on the disease Y that relies on K
observed risk factors X = (X1, � � �, XK) of interest, and the vector Z = (Z1, Z2, � � �) containing all
genetic information of an individual (Fig 1a).
Y ¼ XTβþ f ðU;Z;EYÞ ðif Y is a continuous traitÞ
logit½PðY ¼ 1Þ� ¼ XTβþ f ðU;Z;EYÞ ðif Y is a binary traitÞ
Xk ¼ gkðU;Z;EXkÞ; k ¼ 1; � � � ;K
ð1Þ
Here U represents unknown non-heritable confounding factors and EXk and EY are random
noise acting on Xk and Y respectively. The parameter of interest, β, quantifies the causal effect
of the vector of risk factors X on Y. Mendel’s laws of inheritance suggest that the genotypes Z
are randomized during conception and are generally independent of the environmental factors
(U; EY ;EXk). The function f(U, Z, EY) represents the causal effect of unmeasured risk factors
on Y, which can be heritable (contributed by Z) or non-heritable (contributed by U). The
non-parametric functions f(�) and gk(�) allow interactions among SNPs in Z and variables
(U; EY ;EXk) in their causal effects on X and Y. Under this model, there is horizontal pleiotropy
for a SNP j if Zj has nonzero association with f(U, Z, EY). This is the case, for example, when Zj
acts on Y through a pathway affecting unmeasured risk factors, or when Zj is in linkage dis-
equilibrium (LD) with such a locus.
PLOS GENETICS Causal inference for heritable phenotypic risk factors using heterogeneous genetic instruments
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009575 June 22, 2021 3 / 24
Now consider the case where only GWAS summary statistics, i.e. the estimated marginal
associations between each SNP j and the risk factors/disease traits, are available and there are
in total p SNPs selected. Let Γj be the true association between SNP j and Y, and γj be the vector
of true marginal associations between SNP j and X. Later, we will denote their estimated values
from GWAS summary statistics as Ĝ j and ĝ j. Then, as shown in Materials and Methods, the
model (1) results in the linear relationship
Gj ¼ g
T
j βþ aj ð2Þ
where for binary Y, the parameter β in model (2) is a conservatively biased version of β in
model (1). This relationship holds even when the functions f(�) and gk(�) in (1) are not linear.
Here, αj is the marginal association between Zj and f(U, Z, EY), representing the unknown hor-
izontal pleiotropy of SNP j.
One can immediately see that identifying β is impossible without further assumptions
regarding αj. Early MR methods such as IVW [5] made the assumption that all instruments
Fig 1. Model overview. a, The causal directed graph represented by structural equations (1). b, The existence of a pleiotropic pathway 2 (purple) can result
in multiple modes of the profile likelihood. c, Multi-modality of the profile likelihood can reflect causal direction. d, The work-flow with GRAPPLE.
https://doi.org/10.1371/journal.pgen.1009575.g001
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are valid satisfying αj = 0. Other methods such as Weighted Median [7] or MR-PRSSO [9]
assume that αj is sparsely nonzero. However, the no or sparse pleiotropy assumption follows
from statistical convenience rather than biological insights. As discussed in Introduction, hori-
zontal pleiotropy is pervasive for most complex traits. One assumption that allows pervasive
pleiotropy is to assume the InSIDE assumption [6] where aj⫫gj, or alternatively, the random
effect model [10, 16] where aj � N ð0; t2Þ for most genetic instruments. Unfortunately, the
InSIDE assumption can be easily violated if the pleiotropic effects of selected genetic variants
are driven by shared pleiotropic mechanisms.
Some more recent MR methods such as LCV [26], MRMix [12], Contamination mixture
[13] and CAUSE [15] have noticed this limitation of the InSIDE assumption and allow a subset
of the genetic instruments to be associated with a common hidden pleiotropic pathway. For
instance, using the above notation, both CAUSE and MRMix assumed that when for the SNPs
that violate the inSIDE assumption, their pleiotropic effects satisfy aj ¼ agj þ ~a j (when K = 1)
where aγj represents the correlated pleiotropic effects due to a confounding pathway and
~a j⫫gj. This is a more realistic assumption than InSIDE, though there would then be an issue
in distinguishing the true causal effect β from the pleiotropic direction β + a. Allowing for only
one pleiotropic pathway also makes the model restrictive for real datasets.
Identify multiple pleiotropic pathways and the direction of causality. The key idea
underlying GRAPPLE is that multiple pleiotropic pathways can be detected by using the shape
of the profile likelihood function under no pleiotropy assumption. This allows us to probe the
underlying causal mechanism, without explicit assumptions on pleiotropic patterns (Fig 1b).
When K = 1, the GWAS summary statistics reduce to the scalar ĝ j and Ĝ j, with their standard
errors σ1j and σ2j. From the central limit theorem, the joint distribution of ðĝ j; Ĝ jÞ approxi-


























where θ is a shared sample correlation that can be estimated as ŷ (see Materials and methods).
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where ρ(�) is the Tukey’s Biweight loss, or any other robust loss functions. As described with
more details in Materials and Methods, the profile likelihood is obtained by profiling out nui-
sance parameters γ1, � � �, γp in the full likelihood from (3), which is further robustified by
replacing the L2 loss with Tukey’s Biweight loss to increase the sensitivity of mode detection.
Under no pleiotropy or InSIDE assumption, this function l(b) should have only one mode
near the true causal effect b = β.
Now consider the case where a second genetic pathway (Pathway 2) also contributes sub-
stantially to the disease, and some instrument loci are also associated with Pathway 2 (Fig 1b).
In this scenario, SNPs that are associated with X only through Pathway 2 can contribute to a
second mode in the profile likelihood at location β + κ/δ, where κ and δ quantifies the causal
effect of Pathway 2 on Y and its marginal association with X, respectively (Materials and Meth-
ods). Similarly, multiple pleiotropic pathways generally result in multiple modes of l(b). Thus,
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we can use multiple modes in a plot of l(b) to diagnose the presence of horizontal pleiotropic
effects that are grouped by different pleiotropic pathways.
The existence of pleiotropic pathways complicates MR and makes the causal effects of the
risk factors potentially unidentifiable. Specifically, when Pathway 2 exists, the GWAS summary
statistics alone cannot provide information to distinguish β from β + κ/δ. Instead of making
further untestable assumptions such as one pathway “dominates” the other, when multiple
modes are detected, we suggest that whenever multiple modes are detected, the investigator
should try to find biomarkers for each mode and collect more GWAS data to adjust for con-
founding risk factors. Specifically, GRAPPLE facilitates this by identifying marker SNPs of
each mode, as well as the mapped genes and GWAS traits of each marker SNP (see Materials
and methods). This allows researchers to use their expert knowledge to infer possible con-
founding risk factors that contribute to each mode. With GWAS summary statistics of these
confounding traits, GRAPPLE can perform a multivariable MR analysis assuming the InSIDE
assumption applies for the remaining horizontal pleiotropic effects (Materials and Methods).
The detection of multiple modes can be also used to determine the causal direction (Fig 1c).
If the wrong causal direction is specified in model (1) and Y is a cause of X, the genetic variants
associated with X can be classified in two groups: those associated with X through Y, and those
associated with X through another pathway unrelated to Y. In the former case, γj = βΓj where β
is the causal effect of Y on X, and these SNPs should contribute to a mode around 1/β. In the
latter case, a SNP j satisfies γj 6¼ 0 but Γj = 0, and would contribute to a mode of l(b) at 0. Thus,
there will be two modes in the robust profile likelihood with one mode being around 0. This
idea can be viewed as an extension of the bidirectional MR [29, 30]. Bidirectional MR is based
on the assumptions that when X is a cause of Y, most of the genetic instruments for Y should
be unassociated with X, because they affect Y through a different pathway, thus the reserve MR
would indicate a zero effect of Y on X. GRAPPLE makes this inference more robust by making
use of the fundamentally different shape of the robust profile likelihood plots in different direc-
tions. In the correct causal direction, the plot should only show one mode around the true
causal effect β. In the incorrect reverse direction - when the true outcome is treated as the risk
factor and the true risk factor is treated as the outcome - the plot of the robust profile likeli-
hood will have two modes, one around 0, representing the variants directly related to the
true outcome, and one around 1/β, representing the variants indirectly related to the true
outcome through the true risk factor.
Weak genetic instruments: A curse or a blessing?. Besides the assumption of no-hori-
zontal-pleiotropy, for a SNP to be a valid genetic instrument, it needs to have a non-zero asso-
ciation with the risk factor of interest. In most MR pipelines, SNPs are selected as instruments
only when their p-values are below 10−8, which is required to guarantee a low family-wise
error rate (FWER) for GWAS data. Using such a stringent threshold also helps to avoid weak
instrument bias [31], where measurement errors in ĝ jk are not ignorable and lead to bias in b̂.
However, such a stringent selection threshold may result in very few, or even no instruments
being selected with under-powered GWAS, and may still not be adequate to avoid weak instru-
ment bias. Further, when our goal is to jointly model the effects of multiple risk factors (the
setting where X as a vector), it is unrealistic to assume that all selected SNPs have strong effects
on every risk factor. In addition, the high polygenecity of complex traits indicates that the
weak instruments far outnumbers strong instruments, and collectively, they may substantially
improve the estimation accuracy.
In GRAPPLE, we use a flexible p-value threshold, which can be either as stringent as 10−8
or as relaxed as 10−2, for instrument selection. Based on the profile likelihood framework of
MR-RAPS [10], GRAPPLE can provide valid inference for b̂ that avoids weak instrument bias
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for multiple risk factors even when the p-value threshold is as large as 10−2. This flexible p-
value threshold is beneficial for several reasons. First, including moderate and weak instru-
ments may increase power, especially for under-powered GWAS. Second, for MR with multi-
ple risk factors where it is inevitable to include SNPs that have weak associations with some of
the risk factors, we can obtain much more accurate causal effect estimations than methods that
can only deal with jointly strong SNPs. More importantly, we can investigate the stability of
the estimates across a series of p-value thresholds and get a more complete picture of the
underlying horizontal pleiotropy. In practice, we suggest researchers to vary the selection p-
value thresholds from a stringent one (say 10−8) to a relaxed one (say 10−2), both in the detec-
tion of multiple modes and in estimating causal effects.
The three-sample design to guard against instrument selection bias. The current two-
sample design of MR uses one GWAS data for the risk factor and one for the disease. The
selection of genetic instruments is performed with p-values reported in the GWAS data for the
risk factor. However, selecting instruments from GWAS summary statistics can introduce
bias, which is commonly referred to as the “winner’s curse”. Conditional on being selected, the
magnitude of ĝ jk is generally larger than γjk and introduces bias to the estimation of β. When
K = 1 where there is only one risk factor, the estimate will be biased towards 0, but there is no
guarantee on the direction of the bias when K> 1. Among practitioners, a common belief is
that the selection bias is negligible when only the strongly associated SNPs are selected as
instruments.
However, this rule of thumb may not hold even when we only use that are genome-wide
significant (p-value�10−8) (S1(a) Fig). Thus, we strongly advocate using a three-sample
GWAS summary statistics design (Fig 1d). To avoid the selection bias, selection of genetic
instruments is done on another GWAS dataset for the risk factor, whose cohort has no over-
lapping individuals with both the risk factor and disease cohorts. In addition, to simplify calcu-
lation and avoid bias due to different LD structure in heterogeneous populations, we use LD
clumping [32] to select independent SNPs in GRAPPLE (see Materials and methods). The
three-sample design will also avoid possible selection bias introduced during clumping.
Summarizing the above points, a complete diagram of the GRAPPLE workflow is shown in
Fig 1d. A researcher may start with a single target risk factor of interest. The shape of the
robust profile likelihood provides information on possible pleiotropic pathways. If only a sin-
gle mode is detected, one can use GRAPPLE for the target risk factor. This is equivalent to
using the original MR-RAPS. If multiple modes are detected, the researcher needs to seriously
consider how to adjust for pleiotropic pathways. Researchers can use the marker SNP/gene/
trait information that GRAPPLE provides to investigate each mode, decide on which con-
founding risk factors to adjust for, and collect extra GWAS data for them. GRAPPLE can then
be used to jointly estimate the causal effects of the original and the additional risk factors.
Assessment of GRAPPLE with real studies
Combine weak and strong genetic instruments under no pleiotropy. We first examine
whether GRAPPLE provides reliable statistical inference using instruments with different
strength under an artificial setting with real GWAS summary statistics. In this setting, we
make the “artificial risk factor” X and the “artificial disease” Y be the same trait from two non-
overlapping cohorts, thus γj = Γj while ĝ j 6¼ Ĝ j for any SNP j. Though the structural equation
describing the causal effect of X on Y is not well defined., the linear relationship model (2)
from which we estimate β still holds with β = 1 and αj = 0. In other words, we are not estimat-
ing a meaningful “casual” effect, but are in a special case where the true β is known. This setup
can be used to verify the validity of MR methods under no pleiotropy.
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Specifically, we consider three traits: Body mass index (BMI), Type II diabetes (T2D) and
height from the GIANT and DIAGRAM consortia where sex-specific GWAS data are available
[33–35]. The female cohort is used to get ĝ j and the male cohort is used to get Ĝ j. As a three-
sample design, the UK Biobank data for corresponding traits are used for SNP selection. If we
assume that all selected instruments have no gender-specific association with the traits, the
true β would equal 1. For benchmarking, we compare the performance of GRAPPLE with
CAUSE [15] and three other widely adopted MR methods: inverse-variance weighted (IVW)
[5], MR-Egger [6] and weighted median [7] with the same three-sample design.
We compare different p-value thresholds for instrument selection, ranging from a stringent
threshold of 10−8 to a relaxed threshold of 10−2 (Fig 2a). GRAPPLE provides roughly unbiased
estimates of β no matter which threshold is used, showing that it does not suffer from weak
instrument bias. Surprisingly, the other MR methods are biased even with a stringent p-value
threshold.
Notice that for T2D, the confidence intervals of GRAPPLE do get narrower with increasing
p-value thresholds (Fig 2a), showing the potential power gain of including weak instruments
in less powerful GWAS studies. In addition, we simulate synthetic GWAS summary statistics
of the risk factor and disease (see S1 Text for details) and confirm that the estimated β indeed
gets more accurate with the inclusion of weakly associated SNPs (S2(a) Fig). In the simula-
tions, we also use GRAPPLE to adjust for measured confounding risk factors and compare the
performance with MVMR [36], a commonly used multivariable MR method. As discussed ear-
lier, in multivariable MR, the inclusion of SNPs that are weakly associated with at least one risk
factors is inevitable. As GRAPPLE does not suffer from weak instrument bias, we see that it
provides accurate estimates of the causal effects as well as reliable confidence intervals with
both stringent and mild p-value thresholds (S3–S5 Figs).
Finally, we demonstrate that to avoid bias, the three-sample design is necessary no matter
which MR method is used. As shown in S1(a) Fig, the two-sample design where we use the
same cohort of the risk factor for selection can result in biased casual effects estimation, and
the bias occurs with most MR methods even when we only select the strongly associated SNPs.
Weak SNPs provide reliable causal estimates under pleiotropy. Next, we examine
whether or not the weak instruments are more vulnerable to pleiotropy, which can be a con-
cern for including the weak SNPs. We compare four risk factor and disease pairs that cover
eight different complex traits, including the effect of BMI on T2D, low-density cholesterol con-
centrations (LDL-C) on coronary artery disease (CAD), height on smoking, and systolic blood
pressure (SBP) on stroke (Fig 2b). The GWAS summary data are collected from the original
study repositories [37–42].
We test whether independent sets of strongly and weakly associated SNPs can provide con-
sistent estimates of the causal effects of the risk factors. SNPs passing the p-value threshold 10−2
in the cohort for selection are divided into three non-overlapping groups after LD clumping:
“strong” (pj� 10−8), “moderate” (10−8 < pj� 10−5), and “weak” (10−5 < pj� 10−2). The SNPs
across groups are used separately to obtain group-specific estimates of the causal effect β. We
observe that for all the four pairs, the estimates b̂ are stable across groups (Fig 2b). Though the
“weaker” SNPs provide estimates with more uncertainty due to limited power, the estimates are
consistent with those from the “strong” group. Other MR methods also show some level of con-
sistency in estimating β across different sets of instruments, but perform less well due to weak
instrument bias (S1(b) Fig). To conclude, in the analysis of these four pairs of traits, we do not
see any evidence that weakly associated SNPs provide more biased estimates than strong instru-
ments due to horizontal pleiotropy. In contrast, as with the strong instruments, the weakly asso-
ciated SNPs may also provide useful information to infer the causal effects of the risk factors.
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Fig 2. Performance evaluation. a, Estimation of β across selection p-value thresholds under no pleiotropy. Error bars show 95% Confidence intervals and
the numbers are the number of independent SNPs obtained at each threshold. b, Estimation of β across three non-overlapping categories of SNPs: “strong”,
“moderate” and “weak”. The numbers are the number of SNPs in each category. c, Identifying causal directions by multi-modality with MR reversely
performed. The selection p-value threshold is kept at 10−4. d, three modes detected in the profile likelihood with selection p-value threshold 10−4 for CRP
on CAD. Marker genes and GWAS traits (in parenthesis) are shown for each mode. e, estimation of the CRP effect β at different p-value selection threshold
with each method. The numbers are the estimated b̂, with � indicating p-value below 0.05 and �� indicating p-value below 0.01.
https://doi.org/10.1371/journal.pgen.1009575.g002
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Identify direction of causality for known causal relationships. We also examine the
performance of GRAPPLE in identifying the causal direction with the shape of the profile like-
lihood. For the causal direction, we focus on the two pairs of traits with known causal relation-
ship: BMI on T2D, and LDL-C on CAD. We switch the roles of the risk factor and disease to
see if the correct direction can be revealed. Specifically, we treat T2D and CAD as the “risk fac-
tor”, and BMI and LDL-C as the corresponding “disease” (Fig 2c). For T2D, the cohort for the
other gender is used for SNP selection and for CAD, the risk factor cohort used is from [43]
and the selection p-values are from [44]. As expected, we see that when the roles of the risk
factor and disease are reversed, the robust profile likelihood shows a main mode at 0, and a
weaker mode around 1=b̂.
Detect multiple modes to identify pleiotropic pathways. Finally, we test the ability of
GRAPPLE to identify multiple pleiotropic pathways with the analysis of the C-reactive protein
(CRP) effect on CAD. C-reactive protein has been found to be strongly associated with the risk
of heart disease while many SNPs that are associated with the C-reactive protein also seem to
have pleiotropic effect on lipid traits [45]. Previous MR analyses only included SNPs that are
near the CRP gene to guarantee a free-of-pleiotropy analysis [46, 47] and found that CRP has
no causal effect on CAD. Now, instead of only using SNPs near the CRP gene, by using associ-
ated SNPs across the whole genome that are known to involve pleiotropy pathways, can
GRAPPLE identify the existence of these pathways and still obtain the correct estimate of the
C-reactive protein effect?
CRP GWAS data from [48] are used for selection and the data from [49] using a larger
cohort is used for getting ĝ j. Similar to a multi-modality pattern already reported in [11], our
robust profile likelihood shows a pattern of three modes, indicating the existence of at least
three different pathways (Fig 2d). One mode is negative, one is positive and the third is around
zero. The negative mode involves a few marker genes including HNF1A and PVRL2, with a
marker trait LDL-C. The positive mode has marker traits pulmonary function and the C-reac-
tive protein, and the few markers genes (IL6R, ARHGAP10, BCL7B, PABPC4) are also involved
in immune response and lung cancer progression [50, 51]. The mode at 0 has marker genes
CRP and LEPR, and only one marker trait, C-reactive protein.
We compare across 3 p-value thresholds (10−8, 10−5, 10−3) and check how the existence of
multiple pathways affects causal estimates of the effect of C-reactive protein in MR methods
using SNPs across the genome. Including C-reactive protein as the only risk factor, all bench-
marking methods give a negative estimate of the CRP effect, which is possibly driven by the
bias from an LDL-C induced pleiotropic pathway (Fig 2e). MR-RAPS is the estimation method
used in GRAPPLE if we only use one risk factor, and the three other bench-marking methods
give incorrect inference of the CRP effect with a p-value of β below 0.01 for at least one SNP
selection threshold (notice that the weak instrument bias is towards 0 as shown in Fig 2a, thus
the significance at p-value threshold 10−3 for MR-Egger and IVW cannot be explained by
weak instrument bias). In contrast, after using two risk factors: C-reactive protein and LDL-C,
where LDL-C is an identified confounding risk factor from the marker SNPs in Fig 2d, the esti-
mates of CRP effect are much closer to 0 compared with that without including LDL-C. This
analysis illustrates how GRAPPLE can detect pleiotropic pathways, provide information to
identify the confounding risk factors to adjust for, and obtain correct inference after adjusting
for these risk factors.
As a complement to the analysis on CRP, we also use simulations (S1 Text) and generate
synthetic disease traits to evaluate the precision and recall in the detection of multiple modes
and marker SNPs when there are pleiotropic pathways. We consider scenarios with one or
two pleiotropic pathways caused by hidden confounding risk factors, and vary the genetic
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correlations between these hidden factors and the target risk factor. A higher genetic correla-
tion corresponds to a larger proportion of SNPs that have a correlated pleiotropic effect. We
observe that the detection of multiple modes is most powerful when the genetic correlation is
neither too large nor too small (S2(b) Fig). If the genetic correlation is too high, then there are
not enough SNPs to contribute to the mode of the true causal effect, while if the genetic corre-
lation is too low there will be too few SNPs to contribute to the pleiotropic modes. Including
weaker SNPs will decrease the sensitivity in mode detection but can increase the recall of true
marker SNPs. In our simulations, we also observe that all univariable MR methods can per-
form poorly in estimating the true causal effect in the presence of pleiotropic pathways (S3–S5
Figs).
A causal landscape from 5 risk factors to 25 common diseases
Finally, we apply GRAPPLE to interrogate the causal effects of 5 risk factors on 25 complex dis-
eases. The five risk factors are three plasma lipid traits: LDL-C, high-density lipoprotein cho-
lesterol (HDL-C), triglycerides (TG), BMI and SBP. The diseases include heart disease, Type II
diabetes, kidney disease, common psychiatric disorders, inflammatory disease and cancer (Fig
3a). The GWAS summary statistics are from studies [35, 37, 38, 41, 42, 52–70] and downloaded
from the GWAS catalog [71]. For each pair of the risk factor and disease, we compare across
p-value thresholds from 10−8 to 10−2. As a summary of the results, Fig 3a illustrates the average
number of modes detected across the p-value thresholds for SNP selection (for modes at each
p-value threshold, see S6 Fig). Besides the number of modes, Fig 3a also shows the p-values for
each risk factor when GRAPPLE is performed with only the single risk factor (see also S6 Fig
and Materials and methods). These p-values are not valid when there are pleiotropic pathways.
Fig 3a shows that multi-modality can be detected in many risk factor and disease pairs.
Multi-modality is most easily seen using the stringent p-value threshold 10−8 (S6 Fig). How-
ever, we find that some modes are contributed by a single SNP thus is more likely an outlier
than a pathway. For instance, the effect of stroke on LDL-C shows two modes when the p-
value threshold is 10−8 or 10−7 (one mode around −2.3 and another mode near 0.08). However,
the negative mode only has one marker SNP (rs3184504) which has been found strongly asso-
ciated with hundreds of different traits according to GWAS Catalog while the other mode has
hundreds or marker genes. After removing the SNP rs3184504, the mode disappears. Such a
mode also disappears when we increase the p-value threshold to include more SNPs as instru-
ments. Thus, the average number of modes serves as a strength of evidence for the existence of
multiple pleiotropic pathways. When a risk factor and disease pair show multi-modality, the p-
values from GRAPPLE using the single target risk factor are no longer valid, and the research-
ers need further investigations of the modes.
First, consider the well-studied, often-debated relationship between CAD and the lipid
traits. All five risk factors show highly significant effects, though multi-modality is detected in
HDL-C and SBP. In our results for HDL-C, with different p-value thresholds, three modes in
total can show up, two being negative and one positive, indicating that the pathways from
HDL-C to CAD is complicated (Fig 3b). Fig 3b shows that one negative mode is contributed
by SNPs near genes LPL and BUD13, which are strongly associated with triglycerides. Another
positive mode is contributed by SNPs near genes ALDH1A2 and PSKH1, which is related to
respiratory diseases [72]. The markers of the other negative mode are mapped to genes includ-
ing LIPG and CETP.
Since the effects of the lipid traits are generally complicated, we combine all 5 risk factors
and run an MR jointly with GRAPPLE (Fig 3c) with different p-value thresholds. After adjust-
ing for other risk factors, the two most prominent risk factors for heart disease are LDL-C and
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SBP, while the protective effect of HDL-C stays negligible, as does the risk conferred by TG. So
these results show that HDL-C as a single measurement does not seem to have a protective
effect on heart disease with multiple complex pathways linking HDL-C and heart disease.
Researchers have suggested analyzing different subgroups of HDL-C as smaller particles tend
to have a stronger protective effect [73].
Lipids are also involved in a number of biological functions including energy storage, sig-
naling, and acting as structural components of cell membranes and have been reported to be
associated with various diseases [74–77]. Besides CAD, another disease that most likely
involves the lipid traits is the Type II diabetes (Fig 3a). T2D is associated with dyslipidemia
Fig 3. Screening with GRAPPLE. a, Landscape of pleiotropic pathways on 25 diseases. The colors show average number of modes across 7 different
selection p-value thresholds. The “+” sign shows a positive estimated effect and “−” indicates a negative estimated effect, with the p-value for each cell a
combined p-value (see Materials and methods) of replicability across 7 thresholds using the single risk factor. These p-values are not multiple-testing
adjusted across pairs. b, Multi-modality of the profile likelihood for effect of HDL-C on CAD at 2 different selection p-value threshold. Vertical bars are
positions of marker SNPs (Ĝ j=ĝ j), labeled by their mapped genes (only unique gene names are shown). c, Multivariable MR for the effect of 5 risk factors on
CAD. d, Multivariable MR for the effect of 4 risk factors on CAD. The Error bars are 95% confidence intervals.
https://doi.org/10.1371/journal.pgen.1009575.g003
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(i.e., higher concentrations of TG and LDL-C, and lower concentrations of HDL-C), though
the causal relationship is still unclear [78]. In the meantime, evidence has emerged that LDL-C
reduction with statin therapy results in a modest increase in risk of T2D [74]. For the MR ana-
lyzing each risk factor alone, we see potential protective effects of LDL-C and HDL-C on T2D
but also multi-modality patterns. Two modes show up in the profile likelihood from HDL-C
to T2D where one negative mode has a marker gene LPL and a mode near 0 with marker
genes CETP and AC012181.1. Thus, we include all 3 lipid traits, along with BMI and run a
joint model for these 4 risk factors using GRAPPLE (Fig 3d). Our result indicates a mild
protective effect of HDL-C and LDL-C on T2D, and close to the null but imprecise estimate
for TG.
Discussion
We propose a comprehensive framework, GRAPPLE, that utilizes both strongly and weakly
associated SNPs to understand the causal relationship between complex traits. GRAPPLE is
robust to pervasive pleiotropy and can identify multiple pleiotropic pathways. The multivari-
able MR performed by GRAPPLE can adjust for known confounding risk factors.
GRAPPLE incorporates several improvements over existing MR methods. It avoids weak
instrument bias by dealing with measurement errors of the SNP associations on the risk fac-
tors with profile likelihood. Our likelihood from (9) is similar to the likelihood used in [79],
but our likelihood allows modelling pervasive pleiotropy as long as the InSIDE assumption
holds for most SNPs. The multi-modality visualization shares similarities with [8], which
estimates the causal effect by the global mode, but we provide a more comprehensive analy-
sis to identify multiple pleiotropic pathways by the local modes. Our causality direction
identification is related to bidirectional MR where they used the assumption that if we
reverse the role of risk factor and disease, the estimated causal effect is likely to be 0. We
use this idea in a more principled way and can avoid bias when SNPs affecting the disease
through the target risk factors are also selected as variants for the disease in the reverse MR.
Finally, as the intercept term in MR-Egger is not invariant to the arbitrary assignment of
effect alleles for each SNP, indicating a deficiency of the method, GRAPPLE does not include
any intercept term.
GRAPPLE needs a separate GWAS cohort of the exposure for SNP selection, which is nec-
essary for valid inference with weakly associated SNPs. Actually, as shown in S1(a) Fig, the
three-sample design is needed for other MR methods as well to avoid selection bias. In some
domains, it is hard to obtain multiple good-quality public GWAS summary statistics with
non-overlapping cohorts. We call for the release of stage-specific or study-specific GWAS data
summary statistics to the public in the future.
In GRAPPLE, we still require using a p-value threshold, though it can be as relaxed as 10−2,
instead of requiring no p-value threshold at all. There are two main reasons for this require-
ment. One consideration is to increase power, as including too many SNPs with γj = 0 or
extremely small would instead increase the variance of b̂ [10, 80]. Another consideration is
that we would not want unmeasured risk factors that are unassociated (or very weakly associ-
ated) with target risk factors to bring in large pleiotropic effects with SNPs that mainly affect
these unmeasured risk factors. The chance of including these SNPs would be much lower by
requiring a relaxed p-value threshold.
Finally, when discussing the causal effect of a risk factor, one implicit assumption we use is
consistency, assuming that there is a clear and only one version of intervention that can be
done on the risk factor. However, interventions on risk factors such as BMI are typically vague
[81]. For instance, there can be multiple ways to change weight, such as taking exercise,
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switching to different diet or conducting a surgery. It is common sense that these different
interventions would have different effects on diseases, though they may change BMI by the
same amount. However, the basic MR principle of gene-environment equivalence [82] sug-
gests that whilst there will be genetic mimics of increased physical activity and decreased calo-
rie intake, there will be no such mimics for having surgery. Basic biological principles indicate
which inferences can be sensibly made. For example, cholesterol has multiple functions in our
bodies and is involved in multiple biological processes. Intervening in different biological pro-
cesses to change the concentration of lipid traits may, in principle, have different effects on dis-
ease. However, for many LDL-C lowering drugs the direct genetic mimics produce effects as
predicted by RCTs of these pharmaceutical agents [83], demonstrating that gene-environment
equivalence applies. We think that our causal inference using GRAPPLE, along with the mark-
ers we detect, would provide abundant information to deepen our understanding of the risk
factors. However, one still needs to be careful when giving causal interpretations of the results.




The structural Eq (1) where X = (X1, X2, � � �, XK) and β = (β1, β2, � � �, βK) describe how individ-
ual level data are generated. To link it with the GWAS summary statistics data, denote
gjk ¼ argmingVar½Xk   gZj�
which is the true marginal association between a SNP Zj and risk factor Xk and
aj ¼ argminaVar½f ðU;Z;EYÞ   aZj�
which is the marginal association between Zj and the causal effects of unmeasured risk factors
on Y, i.e. the horizontal pleiotropic effect of Zj on Y given X. Then we can rewrite the structural
equations into the following linear models:
Xk ¼ gjkZj þ ½gkðU;Z; EXkÞ   gjkZj� ¼ gjkZj þ �jk ð5Þ
Y ¼ XTβþ ajZj þ ½f ðU;Z;EYÞ   ajZj� ¼ X
Tβþ ajZj þ ~ej ð6Þ
where corr(Zj, �jk) = 0 for any k and corrðZj;~ejÞ ¼ 0 is guaranteed by the definitions of γjk and
αj. By replacing X in (6) with (5), we get
Y ¼ ðgTj βþ ajÞZj þ ~ej þ
X
k
bk�jk ¼ GjZj þ ej
where Gj ¼ g
T
j βþ aj and ej ¼ ~ej þ
P
kbk�jk. As Corr(Zj, ej) = 0, we conclude that Γj also satis-
fies that
Gj ¼ argminGVar½Y   GZj�:
Thus, parameters Γj also represent true marginal associations between SNP Zj and the dis-
ease trait. This is how we result in working with Eq (2).
When the disease is a binary trait, the structural equation of Y changes to
logit½PðY ¼ 1Þ� ¼ XTβþ f ðU;Z;EYÞ ð7Þ
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With the same argument, we have
logit½PðY ¼ 1Þ� ¼ GjZj þ ej
If we further assume that for each genetic instrument j, Zj is actually independent of ej
(instead of just being uncorrelated), then the odds ratio that is estimated from the marginal
logistic regression will be approximately Γj/c with a constant c> 1 determined by the distribu-
tion of ej. In other words, for binary disease outcomes, Eq (2) is still approximately correct
with the β in (2) being a conservatively biased (by a ratio of 1/c) version of the β in (7) (for a
detailed calculation, see A.1 of [10]).
GWAS summary statistics from overlapping cohorts
The GWAS estimated effect sizes (log odds ratios for binary traits) of SNP j are Ĝ j for the dis-
ease and a length K vector ĝj for the risk factors. As shown in [86] and derived in S2 Text, for
any risk factor k we have





p Corr Ys;Xks½ � ð8Þ
where No and Nek are the total sample sizes for the disease and kth risk factor. Nsk is the num-
ber of shared samples. The correlation of Xk and Y of any shared sample is Corr[Ys, Xks]. Eq



























































































where S is the unknown shared correlation matrix.
Estimate the shared correlation S
To estimate S from summary statistics, we can use Eq (8). We first need to choose SNPs where
γjk = 0 for all risk factors k so that we can estimate the shared correlation Corr ½Ĝ j; ĝ jk� using
the sample correlation of the chosen SNPs. We choose all SNPs whose selection p-values pjk�
0.5 for all k.
For these selected SNPs, denote the Z-values of ðĝ j; Ĝ jÞ for j = 1, � � �, T as matrix ZT×(K+1)
where T is the number of selected SNPs. Then S is estimated as the correlation matrix of
ZT×(K+1).
Instruments selection using LD clumping
In GRAPPLE, we need to first select a set of SNPs as genetic instruments to estimate the causal
effects β. Here, we only select independent SNPs to simplify the calculation. Besides the inde-
pendence requirement, we only include SNPs that pass a p-value threshold to reduce the inclu-
sion of false positives that can decrease power. To avoid selection bias, a separate cohort for
each risk factor is used where the reported p-values in that cohort are used for instruments
selection. Denote the selection p-value for SNP j and risk factor k as pjk, for multiple risk
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factors and a given selection threshold, we require the Bonferroni combined p-values K min
(pjk) to pass the threshold. After that, we use LD clumping with PLINK [87] to select indepen-
dent genetic instruments. The LD r2 threshold for PLINK is set to 0.001.
Estimate the effects β
Here, we perform statistical analysis assuming αj� N(0, τ2) for the pleiotropic effects, while
robust to outliers where the pleiotropic effects for a few instruments are large.
Under model (9), Eq (2) and given S, the log-likelihood with GWAS summary statistics sat-
isfy:
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up to some additive constant. Here, e = (1, 0, � � �, 0).
Define for each SNP j the statistics
tjðβ; t2Þ ¼








where SXj is the variance of ĝ j and SXjYj is the covariance between ĝ j and Ĝ j in Sj. Then the
profile log-likelihood that profile out parameters ðg1; � � � ; gpÞ results in
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As discussed in [10], maximizing Lðβ; t2Þ would not give consistent estimate of τ2. Because
of this and the goal of making β̂ robust to outlier SNPs with large pleiotropic effects, our opti-
mization function is the adjusted robust profile likelihood defined as














1   ð1   ðr=cÞ2Þ3
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if jrj � c
c2=6 otherwise
where c is set to its common default value 4.6851. We maximize (11) with respect to β as well
as solving the following estimating equation for the heterogeneity τ2 which is
φ
2
ðβ; t2Þ ¼ lðβ; t2Þ   pZ ¼ 0 ð12Þ
where Z ¼ E½rðZÞ� with Z � N ð0; 1Þ. The estimating equation satisfies E½φ
2
ðβ; t2Þ� ¼ 0 at
the true values of β and τ2, thus can result in consistent estimate of τ2. For the details of esti-
mating β and τ2 as well building confidence intervals for them, see S2 Text.
PLOS GENETICS Causal inference for heritable phenotypic risk factors using heterogeneous genetic instruments
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009575 June 22, 2021 16 / 24
Identify pleiotropic pathways via the multi-modality diagnosis
We use the mode detection of the robust profile likelihood (11) to detect multiple pleiotropic
pathways. To increase sensitivity, we set τ2 = 0 and reduce the tuning parameter in the Tukey’s
Biweight loss function to c = 3. Here we present a detailed argument on why mode detection
can identify pleiotropic pathways.
If there is a confounding Genetic Pathway 2 ~X , as shown in Fig 1a, that are missed, then we
have the structural equation
Y ¼ bX þ k~X þ f ðU;Z1; � � � ;Zp;EYÞ
and also the linear model
X ¼ d~X þ �; CorrðZj; �Þ ¼ 0: ð13Þ
for a SNP j that only associates with Genetic Pathway 2 and uncorrelates with X conditional on
~X . Similar to (5), we have
X ¼ gjZj þ �j; ~X ¼ ~g jZj þ ~�j
Plug in (13), we have
gj ¼ d~g j
Gj ¼ bgj þ k~g j þ aj ¼ ðbþ k=dÞgj þ aj
Thus, if there are enough SNPs like SNP j, they would contribute to another mode of (4) at
β + κ/δ.
The same argument works for identification of the causal direction. Say there is another ~X
that affects Y but is uncorrelated with the risk factor X (δ = 0). The existence of such ~X is com-
mon, unless X is the only heritable risk factor of Y. SNPs strongly associated with ~X would not
likely be selected when X is the exposure while would appear when the roles of X and Y are
switched. These SNPs can be used to identify the causal direction, as as in the reverse MR, they
contribute to a mode at 0, while the SNPs that affect Y through X will contribute to a mode
at 1/β.
Select marker SNPs and genes for each mode
GRAPPLE uses LD clumping with a stringent r2 (= 0.001) threshold to guarantee indepen-
dence among the genetic instruments. However, marker SNPs are not restricted to these inde-
pendent instruments in order to get more biological meaningful markers. Marker SNPs are
selected from a SNP set G where the SNPs are selected using LD clumping with r2 threshold
0.05.
Assume that there are M modes detected at positions β1, β2, � � �, βM. Define the residual of
SNP j (j 2 G) for mode m as
rjm ¼ tjðbm; 0Þ
where tj(�, �) is defined in Eq (10). SNP j is selected as a marker for mode m if |rjm0|>t1 for any
m0 6¼m and |rjm|�t0. By default, t1 is set to 2 and t0 is set to 1 which gives reasonable results in
practice. When the marker SNPs are selected, GRAPPLE further map the SNPs to ENCODE
genes where the marker SNPs locate and search for the traits that these SNPs are strongly asso-
ciated with in GWA studies by querying HaploReg v4.1 [88] using the R package HaploR. The
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ratios Ĝ j=ĝ j of the marker SNPs are also returned for reference (shown as the vertical bars in
Fig 3b).
Compute replicability p-values across SNP selection thresholds
Each p-value shown in Fig 3a summarizes a vector of p-values across 7 different selection p-
value thresholds ranging from 10−8 ot 10−2 for each risk factor and disease pair. It reflects how
consistent the significance is across SNP selection thresholds. Specifically, it is the partial con-
junction p-value [89] for rejecting the null that β is non-zero for at most 2 of the selection
thresholds. For a risk factor and disease pair k, let the p-values computed by using SNPs
selected with the 7 thresholds pks where s = 1, 2, � � �, 7. Then rank them as pk(1)� pk(2)� � � � �
pk(7), the partial conjunction p-value for the pair k is computed as 5pk(3).
Supporting information
S1 Fig. Additional evaluation results with real data. a, Selection bias in MR methods when
SNP selection and ĝ j are obtained from the same GWAS dataset. True β� 1 and error bars
show 95% confidence intervals. The numbers are the number of clumped SNPs at different
threshold. b, The estimate of β across three independent categories of SNPs with different asso-
ciation strengths for four risk factor and disease pairs using three other bench-marking MR
methods. The numbers are the number of SNPs in each category, separated by the values of
their selection p-values (dashed vertical lines).
(TIFF)
S2 Fig. Simulation results. a, Boxplots of the estimated β1 using different MR methods over
100 repeated random experiments when there are no correlated pleiotropy. We compare
across three different β1 values (0.2, 0.5 and 1) with SNPs selected by three different selection
thresholds: 10−8 for the top 106 SNPs, 10−5 for the top 217 SNPs and 0.01 for the top 422 SNPs.
b, Performance of GRAPPLE in detecting multi-modality. In each setting with pleiotropic
pathways, we evaluate three metrics: the detection rate of multi-modality, the precision of the
identified marker genes of the pleiotropic pathways and the recall of true marker genes that
are identified. Each color represent a different metric and each shape is for a different selection
threshold. The title of each plot shows (β1, � � �, βK) in each setting where β1 is the true causal
effect, and in each setting, we vary the genetic correlation between each genetic confounding
risk factor and the risk factor of interest.
(TIFF)
S3 Fig. Comparison of different MR methods in settings with pleiotropic pathways when
the selection threshold is 10−8 (top 106 SNPs). a, Boxplots of the estimated β1 using different
MR methods over 100 repeated random experiments. b The actual coverage of the 95% confi-
dence intervals of β1 provided by different methods. For CAUSE, we report the coverage of the
95% credible intervals of β1. The red dotted line shows the expected 0.95 nominal level. For the
three settings in the second row with β1 = 0, the CI coverage is the same as 1−type I error.
(TIFF)
S4 Fig. Same as S3 Fig with the selection threshold being 10−5 (top 217 SNPs).
(TIFF)
S5 Fig. Same as S3 Fig with the selection threshold being 10−2 (top 422 SNPs).
(TIFF)
PLOS GENETICS Causal inference for heritable phenotypic risk factors using heterogeneous genetic instruments
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009575 June 22, 2021 18 / 24
S6 Fig. Additional results on identifying pleiotropic pathways on 25 diseases. Each figure is
for results obtained using one of the 7 p-value thresholds. The colors show the number of
detected modes. The “+” sign shows a positive estimated effect and “−” sign shows a negative
estimated effect.
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S1 Text. Simulation details.
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S2 Text. Additional mathematical details of the statistical analysis.
(PDF)
S3 Text. A list of resources for GWAS datasets used in the paper.
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